Sangamo Therapeutics, Inc.
SGMO
$0.44
$0.00-0.82%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -96.83% | 184.39% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -96.83% | 184.39% | |||
| Cost of Revenue | 3.91% | 9.18% | |||
| Gross Profit | -213.98% | 52.21% | |||
| SG&A Expenses | -11.95% | -9.76% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.07% | 3.72% | |||
| Operating Income | -99.12% | 37.19% | |||
| Income Before Tax | -75.82% | 34.51% | |||
| Income Tax Expenses | -696.30% | -77.31% | |||
| Earnings from Continuing Operations | -74.77% | 34.68% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -74.77% | 34.68% | |||
| EBIT | -99.12% | 37.19% | |||
| EBITDA | -104.98% | 38.48% | |||
| EPS Basic | -47.56% | 43.99% | |||
| Normalized Basic EPS | -48.66% | 41.64% | |||
| EPS Diluted | -47.56% | 43.99% | |||
| Normalized Diluted EPS | -48.66% | 41.64% | |||
| Average Basic Shares Outstanding | 18.42% | 16.65% | |||
| Average Diluted Shares Outstanding | 18.42% | 16.65% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||